Lauren A Sanlorenzo1,2, Ann R Stark1,2, Stephen W Patrick1,2,3,4. 1. Department of Pediatrics. 2. Mildred Stahlman Division of Neonatology, Vanderbilt University. 3. Vanderbilt Center for Health Services Research. 4. Department of Health Policy, Vanderbilt University, Nashville, Tennessee, USA.
Abstract
PURPOSE OF REVIEW: The current review provides an update focused on the evolving epidemiology of neonatal abstinence syndrome (NAS), factors influencing disease expression, advances in clinical assessment of withdrawal, novel approaches to NAS treatment, and the emerging role of quality improvement in assessment and management of NAS. RECENT FINDINGS: The rise in the incidence of NAS disproportionately occurred in rural and suburban areas. Polysubstance exposure and genetic polymorphisms have been shown to modify NAS expression and severity. New bedside assessments using a limited number of factors to identify infants with NAS result in fewer infants receiving pharmacotherapy. In addition, buprenorphine may be a promising therapeutic alternative to morphine to treat NAS. Lastly, local, state, and national quality improvement initiatives have emerged as an effective mechanism to advance the care of infants with NAS. SUMMARY: NAS remains a critical public health issue associated with significant medical, economic, and personal burdens. Emerging data on associated risk factors, assessment of and treatment for NAS provide clinicians and hospitals with new knowledge and an urgency to promote standardization of care for infants with NAS.
PURPOSE OF REVIEW: The current review provides an update focused on the evolving epidemiology of neonatal abstinence syndrome (NAS), factors influencing disease expression, advances in clinical assessment of withdrawal, novel approaches to NAS treatment, and the emerging role of quality improvement in assessment and management of NAS. RECENT FINDINGS: The rise in the incidence of NAS disproportionately occurred in rural and suburban areas. Polysubstance exposure and genetic polymorphisms have been shown to modify NAS expression and severity. New bedside assessments using a limited number of factors to identify infants with NAS result in fewer infants receiving pharmacotherapy. In addition, buprenorphine may be a promising therapeutic alternative to morphine to treat NAS. Lastly, local, state, and national quality improvement initiatives have emerged as an effective mechanism to advance the care of infants with NAS. SUMMARY: NAS remains a critical public health issue associated with significant medical, economic, and personal burdens. Emerging data on associated risk factors, assessment of and treatment for NAS provide clinicians and hospitals with new knowledge and an urgency to promote standardization of care for infants with NAS.
Authors: Stephen W Patrick; Robert E Schumacher; Jeffrey D Horbar; Madge E Buus-Frank; Erika M Edwards; Kate A Morrow; Karla R Ferrelli; Alan P Picarillo; Munish Gupta; Roger F Soll Journal: Pediatrics Date: 2016-04-15 Impact factor: 7.124
Authors: Walter K Kraft; Susan C Adeniyi-Jones; Inna Chervoneva; Jay S Greenspan; Diane Abatemarco; Karol Kaltenbach; Michelle E Ehrlich Journal: N Engl J Med Date: 2017-05-04 Impact factor: 91.245
Authors: Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis Journal: JAMA Date: 2012-04-30 Impact factor: 56.272
Authors: Elisha M Wachman; Marie J Hayes; Richard Sherva; Mark S Brown; Jonathan M Davis; Lindsay A Farrer; David A Nielsen Journal: Drug Alcohol Depend Date: 2015-07-08 Impact factor: 4.492
Authors: Jean Y Ko; Stephen W Patrick; Van T Tong; Roshni Patel; Jennifer N Lind; Wanda D Barfield Journal: MMWR Morb Mortal Wkly Rep Date: 2016-08-12 Impact factor: 17.586
Authors: Rishi J Desai; Krista F Huybrechts; Sonia Hernandez-Diaz; Helen Mogun; Elisabetta Patorno; Karol Kaltenbach; Leslie S Kerzner; Brian T Bateman Journal: BMJ Date: 2015-05-14
Authors: Krista F Huybrechts; Brian T Bateman; Rishi J Desai; Sonia Hernandez-Diaz; Kathryn Rough; Helen Mogun; Leslie S Kerzner; Jonathan M Davis; Megan Stover; Devan Bartels; Jennifer Cottral; Elisabetta Patorno Journal: BMJ Date: 2017-08-02
Authors: Katelyn V Chiang; Ekwutosi M Okoroh; Laurin J Kasehagen; Luigi F Garcia-Saavedra; Jean Y Ko Journal: Am J Public Health Date: 2019-07-18 Impact factor: 9.308
Authors: Brooks T McPhail; Chie Emoto; Tsuyoshi Fukuda; Dawn Butler; Jason R Wiles; Henry Akinbi; Alexander A Vinks Journal: J Clin Pharmacol Date: 2019-12-09 Impact factor: 3.126
Authors: Kathleen M Doherty; Theresa A Scott; Anna Morad; Travis Crook; Elizabeth McNeer; Kim S Lovell; James C Gay; Stephen W Patrick Journal: Pediatrics Date: 2020-12-02 Impact factor: 7.124
Authors: Emery R Eaves; Jarrett Barber; Ryann Whealy; Sara A Clancey; Rita Wright; Jill Hager Cocking; Joseph Spadafino; Crystal M Hepp Journal: PLoS One Date: 2021-06-03 Impact factor: 3.752